DKK1 as a robust predictor for adjuvant platinum chemotherapy benefit in resectable pStage II-III gastric cancer

Zhiyuan Fan a,b,1, Beiqin Yu a,1, Tao Pan a, Fangyuan Li a, Jianfang Li a, Junyi Hou a, Wentao Liu a, Liping Su a, Zhenggang Zhu a, Chao Yan a,b,*, Bingya Liu a,b,*

a Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
b Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai 200092, China

ABSTRACT

Background: Adjuvant chemotherapy (ACT) with 5-FU alone or 5-FU plus platinum after curative surgery improves the prognosis of pStage II-III gastric cancer (GC). However, only a subset of patients benefits from adjuvant platinum. To avoid the side effects of platinum, it is significant to accurately screen the patients who would benefit maximally with this treatment. The present study aimed to assess the value of DKK1 in predicting the benefit of adjuvant platinum chemotherapy in patients with pStage II -III GC.

Methods: Platinum sensitivity-related genes were screened by bioinformatics. DKK1 expression in 380 GC specimens was detected by immunohistochemistry (IHC) staining, and the correlation with adjuvant platinum-specific benefits were analyzed.

Results: DKK1 was screened as the most significant platinum sensitivity-related gene. In patients with DKK1 high GC, the estimated absolute 5-year overall survival (OS) benefits from adjuvant platinum for pStage II-III, II, IIIA, IIIB, and IIIC were 25.5%, 17.3%, 36.4%, 29.2% and 31.1%, respectively, and the estimated absolute 5-year disease-free survival (DFS) benefits in the corresponding stages were 27.4%, 17.5%, 36.7%, 29.7% and 31.5%, respectively. These benefits were significantly higher than those in the same TNM stage without adjusting for DKK1 status. The performance of DKK1 was independent of the TNM stage and other clinicopathological variables. Similar results were obtained in the TCGA and ACRG cohorts. Furthermore, nomograms were constructed to predict the survival benefits in DKK1 subgroups.

Conclusions: The stratification strategy based on DKK1 status is more precise than the TNM staging system for the selection of pStage II-III GC patients suitable for platinum-containing ACT.

Introduction

Gastric cancer (GC) is the sixth most common cancer and the third leading cause of cancer-related deaths worldwide [1], and has been ranked second in both the incidence and mortality of cancers in China [2]. Most patients have advanced disease at diagnosis. Adjuvant chemotherapy (ACT) after curative D2 gastrectomy prevents relapse and improves survival compared to curative surgery alone for patients with pStage II-III GC according to two phase III trials: ACTS-GC and CLASSIC [3,6]. According to the two studies, ACT with S-1 alone or the capcetabine plus oxaliplatin (XELOX) has been recommended as the standard of care for patients with pStage II-III GC. However, the survival benefits in both studies are similar but limited. The absolute 5-year overall survival (OS) benefit from ACT in the ACTS-GC and CLASSIC trials is 10.6% and 9%, respectively [4,6], suggesting that only a few patients benefit from these approaches. The current standard ACT regimen can be summarized as the single-drug (5-FU or its derivatives alone) and double-drug (5-FU or its derivatives plus platinum) regimens. The double-drug regimen increases the adverse events due to the addition of platinum [3,5,7]. To date, high-quality phase III clinical trials to directly compare the single- and double-drug regimens are lacking, but the consensus on ACT regimens has not been reached. Recently, Kim et al. [8] compared the efficacy of adjuvant S-1 vs. XELOX among 1088 patients with GC after D2 surgery and found that adjuvant XELOX was

https://doi.org/10.1016/j.tranon.2022.101577
Received 24 August 2022; Received in revised form 5 October 2022; Accepted 19 October 2022
1936-5233/© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
more effective than S-1 in pStage IIIB and IIIC but not in pStage II-IIIA. Also, in pStage IIIB and IIIC, the benefit of oxaliplatin is limited. Therefore, screening patients suitable for ACT and further determining whether these patients should receive platinum-containing regimen is essential. Recent studies have developed some patient stratification methods to predict the benefits of general ACT, according to either biomarkers [9–13] or clinical characteristic-based models [14]. However, efficient methods to direct chemotherapy regimen selection are lacking.

In this retrospective study, we aimed to evaluate the power of the platinum sensitivity-associated gene for predicting the survival benefit of adjuvant platinum in patients with resectable pStage II-III GC. Therefore, we identified Dickkopf-1 (DKK1) as a biomarker with a robust prediction power and developed nomograms to predict the survival benefits in DKK1 subgroups.

Materials and methods

Ethics approval and consent to participate

This study was approved by an institutional review board of the Human Research Ethics Committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (Shanghai, China) and conducted in accordance with ethical guidelines (Declaration of Helsinki). All the sample studies were conducted after obtaining written consent from all patients.
Analysis of platinum sensitivity-related genes in GC cell lines

The gene expression profile data of 20 GC cell lines and their IC_{50} data to cisplatin (CDDP) and 5-FU were downloaded from the GDSC database (https://www.cancerrxgene.org/) [15] and differentially expressed gene (DEG) analysis between CDDP-resistant and -sensitive GC cell lines was performed using the limma package [16]. The standard for DEG was fold change (FC) \( \geq 2 \) (or \( \leq 0.5 \)) and unpaired t-test \( P \)-value \( < 0.05 \).

Analysis of DKK1 expression in TCGA and ACRG molecular subtypes of GC

DKK1 expression data in the TCGA and ACRG GC cohorts were downloaded from the TCGA (http://cancergenome.nih.gov/) and the GEO database (http://www.ncbi.nlm.nih.gov/geo/) (accession number: GSE62254), respectively. The molecular subtype information was obtained from the original articles [17,18].

Patients and tumors

A retrospective study was conducted on 380 gastric adenocarcinoma patients who underwent curative D2 gastrectomy between September 2008 and 2012 at Shanghai Ruijin Hospital. All patients, \( \geq 18 \)-years-old, had a pathological TNM stage of II-III (pStage II-III), and had not received preoperative radiotherapy/chemotherapy or combined malignant neoplasm. All patients had received ACT; 114 were treated with 5-FU or its derivatives alone (the single-drug group), 266 were treated with 5-FU or its derivatives plus platinum (the double-drug group). The FFPE specimens for the primary tumors of all patients were collected for immunohistochemical (IHC) staining to assess DKK1 expression. The patient characteristics included age, gender, tumor site, tumor size, tumor differentiation, nerve invasion status and TNM stage. All patients were staged according to the American Joint Committee on Cancer (AJCC) cancer staging manual (seventh edition) [19] and followed up routinely. Overall survival (OS) was defined as the time from the date of first pathological diagnosis to the date of death from any cause or the last date of follow-up, while relapse-free survival (RFS) was defined as the time from the date of radical surgery to the time of recurrence, development of a new GC, death from any cause or the last date of
The primary antibody was rabbit antibody against human DKK1 (Abcam, Cat#ab109416). The secondary anti-

Table 1

| Characteristics | OS Double-drug vs. single-drugHR (95% CI) Log-rank P | RFS Double-drug vs. single-drugHR (95% CI) Log-rank P | Pinteraction |
|-----------------|---------------------------------------------------|--------------------------------------------------|--------------|
| Age (years)     |                                                   |                                                  | 0.15         | 0.14 |
| < 60            | 0.38 (0.18-0.79)                                  | 0.007                                            | 0.40 (0.20-0.80) | 0.0994 |
| ≥ 60            | 0.41 (0.26-0.64)                                  | 0.00012                                          | 0.39 (0.25-0.61) | 3.27e-05 |
| Gender          |                                                   |                                                  | 0.59         | 0.62 |
| Male            | 0.42 (0.27-0.67)                                  | 0.00022                                          | 0.44 (0.29-0.67) | 0.00017 |
| Female          | 0.37 (0.19-0.70)                                  | 0.0024                                           | 0.40 (0.22-0.74) | 0.0034 |
| Tumor size (cm) |                                                   |                                                  | 0.031        | 0.030 |
| < 5             | 0.54 (0.33-0.89)                                  | 0.014                                            | 0.52 (0.33-0.82) | 0.0048 |
| ≥ 5             | 0.27 (0.15-0.47)                                  | 4.95e-06                                         | 0.28 (0.16-0.49) | 5.51e-06 |
| Tumor differentiation |                                   |                                                  | 0.0011        | 0.0030 |
| Well-differentiated | 0.46 (0.16-1.35)                           | 0.16                                             | 0.32 (0.12-0.86) | 0.0247 |
| Poor-differentiated | 0.41 (0.28-0.61)                        | 6.07e-6                                          | 0.44 (0.30-0.63) | 1.13e-05 |
| Tumor site      |                                                   |                                                  | 0.67         | 0.67 |
| Antral          | 0.37 (0.24-0.58)                                  | 1.57e-05                                         | 0.36 (0.23-0.55) | 2.69e-06 |
| GEJ*            | NA                                                | NA                                               | NA           | NA |
| Body            | 0.31 (0.14-0.68)                                  | 0.0036                                           | 0.35 (0.17-0.71) | 0.0042 |
| Multisite       | 0.76 (0.095-5.99)                                 | 0.79                                             | 0.76 (0.095-5.99) | 0.79 |
| Nerve invasion  |                                                   |                                                  | 0.052        | 0.011 |
| No              | 0.50 (0.31-0.79)                                  | 0.00033                                          | 0.47 (0.30-0.73) | 0.00072 |
| Yes             | 0.31 (0.17-0.56)                                  | 0.00011                                          | 0.33 (0.18-0.58) | 0.00012 |
| T stage         |                                                   |                                                  | 0.054        | 0.048 |
| T1–2a           | 0.45 (0.12-1.69)                                  | 0.24                                             | 0.46 (0.12-1.75) | 0.26 |
| T3–4            | 0.43 (0.29-0.62)                                  | 8.78e-06                                         | 0.44 (0.31-0.62) | 5.74e-06 |
| N stage         |                                                   |                                                  | 4.35e-06     | 1.60e-06 |
| N0              | 0.47 (0.17-1.28)                                  | 0.14                                             | 0.47 (0.18-1.19) | 0.11 |
| N1              | 0.80 (0.30-2.16)                                  | 0.67                                             | 0.66 (0.26-1.68) | 0.38 |
| N2              | 0.20 (0.09-0.44)                                  | 3.92e-05                                         | 0.21 (0.10-0.44) | 3.10e-05 |
| N3              | 0.43 (0.23-0.79)                                  | 0.0068                                           | 0.49 (0.27-0.89) | 0.018 |
| TNM stage       |                                                   |                                                  | 6.02e-09     | 3.00e-11 |
| II              | 0.38 (0.15-1.00)                                  | 0.050                                            | 0.45 (0.18-1.13) | 0.088 |
| IIIA            | 0.61 (0.21-1.73)                                  | 0.35                                             | 0.48 (0.18-1.28) | 0.14 |
| IIIB            | 0.40 (0.20-0.81)                                  | 0.011                                            | 0.35 (0.18-0.71) | 0.0037 |
| IIC             | 0.35 (0.19-0.64)                                  | 0.00069                                          | 0.40 (0.23-0.70) | 0.0014 |
| DKK1 expression |                                                   |                                                  | 3.08e-11     | 4.41e-8 |
| Low             | 0.89 (0.54-1.48)                                  | 0.66                                             | 0.86 (0.54-1.39) | 0.54 |
| High            | 0.19 (0.11-0.33)                                  | 9.13e-09                                         | 0.18 (0.11-0.32) | 2.24e-09 |
| Overall         | 0.43 (0.30-0.61)                                  | 3.52e-06                                         | 0.43 (0.31-0.61) | 1.44e-06 |

Table footnotes:

1 GEJ, gastroesophageal junction

2 There are 14 T1b (early gastric cancer) cases, all of whom have a pN stage N2-3.

Follow-up. The median follow-up for OS and RFS were 75.0 and 74.3 months, respectively.

**IHC staining**

For IHC staining, all the steps were performed according to a standard LSAB protocol (Dako). The primary antibody was rabbit antibody against human DKK1 (Abcam, Cat#ab109416). The secondary antibodies were biotinylated swine anti-rabbit antibody (Dako). The protein level of DKK1 was detected mainly in the plasma membrane and cytoplasm. Medium to strong positivity for > 20% of the cancer cells was defined as DKK1high. The omission of the primary antibody served as the negative control.

**Statistical analysis**

All statistical analyses were performed using the R 3.6.1 software. A two-sided P < 0.05 was considered statistically significant. Chi-square test, Fisher’s exact test, Cochran–Mantel–Haenszel test, and linear trend test was applied to compare enumeration variables. The OS and RFS were evaluated using the Kaplan-Meier survival curves and the log-rank test. Variables that achieved statistical significance at P < 0.05 in univariate analyses were included into the multivariate analyses. Multivariate analyses based on the Cox proportional hazards (Coxph) regression model determined the interactions among variables and whether a variable was an independent predictor for survival. Variables that met the following two criteria at the same time were defined as the independent predictors for adjuvant platinum benefits: (i) log-rank test P < 0.05 (double-drug vs single-drug) of multivariate analysis in at least one subgroup of a variate, (ii) Pinteraction < 0.05 (interaction between this variable and ACT regimen) in multivariate analysis.

Variables that were defined as the independent predictors in multivariate analyses were used to construct nomograms. Nomograms were constructed using the package of rms in R version R 3.6.1 (http://www.r-project.org/) as described in a previous study [20]. A backward step-down selection process with the Akaike information criterion was performed for a final model selection. The performance of the nomogram was measured by concordance index (C-index) and the calibration curves were drawn to compare the nomogram-predicted vs. the Kaplan-Meier curve-estimated actual survival probability using bootstrap with 1000 resampling [14,20,21]. A larger C-index means more accurate for the prediction of patient prognosis. The and calibration curves and C-indexes were derived based on the regression analysis and P < 0.05 was considered statistically significant.

**Results**

**DKK1 expression is associated with platinum sensitivity in GC cell lines**

To screen the platinum sensitivity-related genes, two DEG strategies were applied. The comparison of the top 5 CDDP-resistant vs. -sensitive GC cell lines identified 233 DEGs (DEG1) (Fig. 1a; Table S1, supporting information), while the comparison of the top 10 CDDP-resistant versus -sensitive GC cell lines identified 113 DEGs (DEG2) (Fig. 1b; Table S1,
supporting information). A total of 33 genes were common DEGs (Fig. 1c; Table S2, supporting information); 23/33 (69.7%) were down-regulated in CDDP-resistant GC cells and DKK1 was the most significant DEG in both strategies (86.23-fold down-regulated, P = 0.0014 in DEG1; 10.04-fold down-regulated, P = 0.0001 in DEG2) (Fig. 1a and 1b; Table S2, supporting information). The FC of the 10 common DEGs was observed in 184 (48.4%) and 196 (51.6%) GC, respectively. The typical DKK1 staining in normal and different stages of GC is shown in Fig. 2 a. We did not observe an attribution difference in the clinicopathological parameters between the DKK1low and DKK1high subtypes (Table S3, supporting information). The DKK1low group had a significantly poorer OS and DFS than the DKK1high group (Fig. 1c and d). Furthermore, DKK1low was an independent predictor for poor OS and patients’ DFS (Tables S4 and S5, supporting information).

**DKK1 expression is associated with TCGA and ACRG molecular subtypes of GC**

To evaluate the association between DKK1 expression and GC molecular subtypes, we analyzed the TCGA and ACRG cohorts and found that the expression level of DKK1 in ACRG MSS/TP53- and MSS/TP53+ subtypes was significantly higher than that in the MSI and GS subtypes (Fig. 1f; Pearson r = 0.22, P = 0.42). The CDDP IC50 in DKK1high GC cells were significantly lower than those in DKK1low GC cells (Fig. 1e; P = 0.022), and the 5-FU IC50 were similar between the two groups (Fig. 1g; P = 0.80). These data suggested that DKK1 is associated with platinum sensitivity in GC cells.

**Low expression of DKK1 is positively associated with poor prognosis of pStage II-III patients**

To evaluate the DKK1 expression pattern in primary GC lesions of 380 patients receiving ACT after radical surgery, the protein levels in specimens were detected by IHC. DKK1low and DKK1high were observed in 184 (48.4%) and 196 (51.6%) GC, respectively. The typical DKK1 staining in normal and different stages of GC is shown in Fig. 1a. We did not observe an attribution difference in the clinicopathological parameters between the DKK1low and DKK1high groups (Table S3, supporting information). The DKK1low group had a significantly poorer OS and DFS than the DKK1high group (Fig. 1c and d). Furthermore, DKK1low was an independent predictor for poor OS and patients’ DFS (Tables S4 and S5, supporting information).

**DKK1 expression is a robust predictor for adjuvant platinum chemotherapy benefit in pStage II-III patients after radical D2 surgery**

In the IHC cohort, patients in the double-drug group were younger and had later TNM stages than those in the single-drug group, and the remaining baseline characteristics, including the usage of fluorouracil drugs between the two groups were similar (Table S6, supporting information). Essentially, the platinum drug used in the double-drug group was oxaliplatin (256/266, 96.2%) (Table S6, supporting information). In the overall pStage II-III GC patients, the OS and DFS benefit from adjuvant platinum were significant in both univariate and multivariate analyses (Figs. S1a and S2a, Tables 1, S7 and S8, supporting information). However, these survival benefits were very limited. The estimated absolute 5-year OS and DFS benefits from adjuvant platinum were only 5.5% and 6.9%, respectively (Tables S7 and S8, supporting information). We also observed that the OS and DFS benefit from adjuvant platinum were significant in pStage III patients rather than in pStage II patients in both univariate and multivariate analyses (Figs. S1b, S1c, S2b and S2c, Tables S7 and S8, supporting information; Table 1). Next, we observed that pStage IIIA and IIIB patients obtained significant OS and DFS benefits from adjuvant platinum in both the univariate and multivariate analysis (all P < 0.05), while pStage IIIA patients did not obtain significant OS and DFS benefits (both P > 0.05 in multivariate analysis) (Figs. S1b, S1c, S2b and S2c, Tables S7 and S8, supporting information).
favorable prognosis for long-term OS benefit from adjuvant platinum, and tumor size, tumor differentiation, nerve invasion, T stage, N stage, TNM stage and DKK1 status as the independent predictors of survival benefit of adjuvant platinum in pStage II-III patients.

Development of nomogram prediction models for adjuvant platinum chemotherapy benefits in DKK1 subgroups

In multivariate analysis, we identified tumor size, tumor differentiation, N stage, TNM stage and DKK1 status as independent predictors for long-term OS benefit from adjuvant platinum, and tumor size, tumor differentiation, nerve invasion, T stage, N stage, TNM stage and DKK1 status as independent predictors for long-term RFS benefit from adjuvant platinum.

supporting information; Table 1). The estimated absolute 5-year OS and RFS benefits from adjuvant platinum chemotherapy were 14.3% and 21.4% in pStage IIIB patients, and 13.3% and 16.6% in pStage IIIC patients, respectively. In summary, the OS benefit from adjuvant platinum in pStage II-III GC patients is limited, especially in pStage II-IIIA patients; the benefit may limit to only a few patients. Thus, more efficient strategies other than the TNM staging system are essential.

To evaluate the clinical validity of DKK1 expression in predicting adjuvant platinum benefit, the predictive power of DKK1 status was investigated. We found that adjuvant platinum significantly improved the OS and RFS in patients with DKK1 (Figs. 3 and 4; Tables S7 and S8, supporting information; double-drug vs single-drug, HR 0.33, CI 0.13-0.86, P = 0.033 for OS of pStage II and HR 0.23, 95% CI 0.045-0.99, P = 0.047 for RFS of pStage II; HR 0.31, 95% CI 0.096-0.37, P < 0.0001 for OS of pStage III and HR 0.20, 95% CI 0.10-0.39, P < 0.0001 for RFS of pStage III; HR 0.20, 95% CI 0.08-0.68, P = 0.018 for OS of pStage IIIA and HR 0.10, 95% CI 0.016-0.65, P = 0.015 for RFS of pStage IIIA; HR 0.31, 95% CI 0.083-0.65, P = 0.0061 for OS of pStage IIIIB and HR 0.23, 95% CI 0.081-0.66, P = 0.0059 for RFS of pStage IIIIB; HR 0.22, 95% CI 0.016-0.28, P < 0.0001 for OS of pStage IIIIB and HR 0.078, 95% CI 0.024-0.28, P < 0.0001 for RFS of pStage IIIIC) but not in patients with DKK1 tumors (Figs. 3 and 4; Tables S7 and S8, supporting information; double-drug vs single-drug, HR 1.31, 95% CI 0.84-2.00, P = 0.24 for OS of overall pStage II-III and HR 1.25, 95% CI 0.82-1.90, P = 0.30 for RFS of overall pStage II-III; HR 0.84, 95% CI 0.27-2.63, P = 0.77 for OS of pStage II and HR 0.84, 95% CI 0.27-2.62, P = 0.77 for RFS of pStage II; HR 0.79, 95% CI 0.44-1.35, P = 0.36 for OS of pStage III and HR 0.75, 95% CI 0.44-1.28, P = 0.30 for RFS of pStage III; HR 0.96, 95% CI 0.24-3.86, P = 0.95 for OS of pStage IIIA and HR 0.70, 95% CI 0.19-2.65, P = 0.60 for RFS of pStage IIIA; HR 0.62, 95% CI 0.23-1.47, P = 0.025 for OS of pStage IIIB and HR 0.51, 95% CI 0.20-1.26, P = 0.14 for RFS of pStage IIIB; HR 0.61, 95% CI 0.21-1.43, P = 0.22 for OS of pStage IIIC and HR 0.63, 95% CI 0.26-1.51, P = 0.030 for RFS of pStage IIIC) in univariate analysis. In patients with DKK1 tumors, the estimated absolute 5-year OS and RFS benefits from adjuvant platinum were 25.5% and 27.4% in the overall pStage II-III, 17.3% and 17.5% in pStage II, 36.4% and 36.7% in pStage IIIA, 29.2% and 29.7% in pStage IIIB, and 31.1% and 31.5% in pStage IIIC in univariate analysis (Figs. 3 and 4; Tables S7 and S8, supporting information), and were significantly higher than those in the same TNM stage without adjusting for DKK1 status (Figs. S1 and S2, Tables S7 and S8, supporting information). The survival benefits from adjuvant platinum in patients with DKK1 tumors were significant in multivariate analysis (Table 1; HR 0.19, 95% CI 0.11-0.33, P = 9.13e-09 for OS of pStage III and HR 0.18, 95% CI 0.11-0.32, P = 2.24e-09 for RFS). Also, the interaction between DKK1 status and adjuvant platinum benefits was significant (Tables S7 and S8, supporting information, in univariate analysis, Pinteraction = 0.00048 for OS benefit and Pinteraction = 0.00014 for RFS benefit; Table 1, in multivariate analysis, Pinteraction = 3.08e-11 for OS benefit and Pinteraction = 4.41e-8 for RFS benefit). We further validated the ability of DKK1 status to determine the survival benefits from adjuvant platinum in the TCGA and ACRG cohorts (Fig. S3, supporting information). In summary, high expression of DKK1 is an independent and robust predictor of survival benefits of adjuvant platinum in pStage II-III patients.
Fig. 5. Survival nomograms for OS and RFS of patients with DKK1\textsuperscript{high} pStage II-III GC in the IHC cohort. a For OS, b For RFS. For an individual patient, nomogram a was used to calculate the estimated 3- and 5-year OS with double-drug or with single-drug ACT, and nomogram b was used to calculate the estimated 3- and 5-year RFS with double-drug or with single-drug ACT. The difference between the two predicted values is the estimated absolute 3- and 5-year OS and RFS improvements as a result of adjuvant platinum chemotherapy.
Platinum-containing ACT. However, other efficient methods are yet to be selected the appropriate ACT regimen. The subgroup analysis of the adjuvant platinum in the clinical subgroups of patients with DKK1 II-IIIA GC. In the DKK1 high benefit, especially in patients with pStage II-IIIA GC is an urgent limited value of TNM staging system in directing the selection of curative surgery only, curative surgery plus single-drug ACT, or plus 5-FU plus platinum was the most significant prognostic factor for both OS and RFS of patients with DKK1 high pStage II-III tumors but a weak prognostic factor for both OS and RFS of patients with DKK1 low pStage II-III tumors. The C-indexes for OS and RFS prediction in patients with DKK1 high pStage II-III GC were 0.79 (95% CI 0.73-0.85) and 0.78 (95% CI 0.74-0.82), respectively. The C-indexes for OS and RFS prediction in patients with DKK1 low pStage II-III GC were 0.69 (95% CI 0.65-0.73) and 0.71 (95% CI 0.66-0.76), respectively. The calibration curve for the probability of OS and RFS at 3 or 5 year showed an optimal agreement between the prediction by nomogram and the actual observation in the DKK1 high group (Fig. S5, supporting information) and in the DKK1 low group (Fig. S6, supporting information). According to these nomograms, we could predict the absolute 5-year OS and RFS improvements from adjuvant platinum in the clinical subgroups of patients with DKK1 high and DKK1 low tumors. This finding further confirmed that the predicted absolute 5-year OS and RFS improvements from adjuvant platinum in the DKK1 high group were significantly greater than those in the DKK1 low group when patients were stratified by the variables in the nomograms (Tables S9 and S10, supporting information). Regarding the OS of patients in the DKK1 high group with a specific TNM stage, those with tumors \( \geq 5 \) cm and poor differentiation might benefit maximally, while those with small tumors (< 5cm) and well differentiation might benefit the least from adjuvant platinum. For the RFS of patients in the DKK1 high group with a given TNM stage, those with large tumors (> 5 cm), poor differentiation, and nerve invasion might benefit maximally most from adjuvant platinum, while those with small tumors (< 5cm), well differentiation and without nerve invasion might benefit the least from adjuvant platinum (Tables S9 and S10, supporting information).

Discussion

Accurate stratification of patients with pStage II-III GC to receive curative surgery only, curative surgery plus single-drug ACT, or plus double-drug ACT is clinically significant because it allows the patients to avoid huge side effects. The TNM staging system is a major determinant in selecting the appropriate ACT regimen. The subgroup analysis of the ACTS-GC trial showed that patients with pStage II and IIIA rather than pStage IIIB GC benefitted significantly from adjuvant S-1 monotherapy [3,4]. The subgroup analysis of the CLASSIC trial showed that patients with pStage II, IIIA, and IIIB GC benefit from adjuvant XELOX [5,6]. Two recent retrospective studies [7,8] showed that the significant survival benefit advantage of adjuvant XELOX vs. S-1 alone was observed only in pStage IIIC. Moreover, the results of pStage IIIB were inconsistent in the two studies. The current study showed that pStage IIIB and IIIC rather than pStage II-IIIA patients benefitted significantly from adjuvant platinum, which was consistent with the above-mentioned two studies. The estimated absolute 5-year OS benefit from adjuvant platinum in pStage IIIB and IIIC patients was only moderate. These findings suggested a limited value of TNM staging system in directing the selection of platinum-containing ACT. However, other efficient methods are yet lacking. Therefore, a precise method for predicting adjuvant platinum benefit, especially in patients with pStage II-IIIA GC is an urgent requirement. Herein, we identified DKK1 as a robust predictor for benefits from adjuvant platinum in patients with both pStage IIIB-IIIC and II-IIIA GC. In the DKK1 high group, patients with pStage II and IIIA GC showed an improvement in the 5-year OS improvements of 17.3% and 36.4%, respectively. The performance of DKK1 was independent of the TNM stage and other variables; similar results were observed in the TCGA and ACRG cohorts. Furthermore, we developed nomograms to predict the survival benefits in DKK1 subgroups. Thus, our study demonstrated a more robust method than the TNM staging system to determine whether a patient should receive platinum-containing ACT.

DKK1 is an antagonist of the canonical Wnt/β-catenin signaling [22, 23]. Both oncogene-like [23-25] and tumor suppressor-like [25,26,27] functions of DKK1 have been reported in other cancers, while opposite results have been reported on the correlation between DKK1 expression and GC patient prognosis [28-33]. High level of DKK1 was associated with poor prognosis in most studies [31-33]. However, Jia et al. [29] reported that low expression of DKK1 was associated with poor prognosis, and silencing DKK1 in GC cells led to resistance to cisplatin and promoted cell proliferation and invasion. Cai et al. [34] and Wang et al. [30] showed that DKK1 reduces self-renewal of cancer stem-like cells and tumorigenicity in GC cells by attenuating Wnt signaling. These pieces of evidence indicated that DKK1 plays a tumor suppressor role in GC. The current study showed that the low expression of DKK1 was an independent predictor for the poor prognosis of pStage II-III GC patients who received ACT after radical surgery, which was consistent with the findings of Jia et al. [29] but not the other studies. Notably, all previous studies did not consider ACT. Interestingly, the high expression of DKK1 may be associated with poor prognosis because we observed this trend in patients who received adjuvant 5-FU alone. Similar observations were reported in lung cancer [35], which showed that poor prognoses associated with low RPS could be negated by chemotherapy because low-RPS tumors are sensitive to platinum. Therefore, the converse prognostic impact of DKK1 can be explained by heterogeneous patient cohorts, especially the heterogeneity of ACT. In addition, the mechanisms underlying the association between DKK1 expression and platinum sensitivity are yet to be clarified. Herein, we inferred that Wnt signaling might be involved in platinum resistance and its inhibition of the Wnt signaling might reverse the platinum resistance, showing a synergistic anti-tumor effect in DKK1 low GC.

Conclusions

In summary, we provide a robust patient stratification strategy to select pStage II-III suitable GC patients who would receive platinum-containing ACT according to DKK1 status. However, these results need to be substantiated further in subsequent prospective, larger, multi-centered randomized clinical trials.

Availability of data and materials

The data that support the findings of this study are available upon request from the corresponding author.

CRediT authorship contribution statement

Zhiyuan Fan: Conceptualization, Data curation, Writing – original draft. Beiqin Yu: Methodology, Software, Writing – review & editing, Funding acquisition. Tao Pan: Formal analysis. Fangyuan Li: Investigation. Jianfang Li: Resources. Junyi Hou: Validation. Wentao Liu: Visualization, Supervision. Liping Su: Visualization, Supervision. Zhenggang Zhu: Supervision, Funding acquisition. Chao Yan: Conceptualization, Supervision. Bingya Liu: Conceptualization, Supervision, Writing – review & editing, Funding acquisition.

Declaration of Competing Interest

The authors declare no conflict of interests.

Acknowledgments

We thank all the participants of the Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine.
Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi: 10.1016/j.tranon.2022.101577.

References

[1] F. Bray, J. Ferlay, I. Soerjomataram, et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. 68 (2018) 394–424.

[2] W. Chen, R. Zheng, P.D. Baade, et al., Cancer statistics in China, 2015, CA Cancer J. Clin. 66 (2016) 115–132.

[3] S. Sakuramoto, M. Sasaki, T. Yamaguchi, et al., Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidin, N Engl. J. Med. 357 (2007) 1810–1820.

[4] M. Sasaki, S. Sakuramoto, H. Katai, et al., Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer, J. Clin. Oncol. 29 (2011) 4387–4393.

[5] Y.J. Bang, Y.W. Kim, H.K. Yang, et al., Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomized controlled trial, Lancet 379 (2012) 315–321.

[6] S.H. Noh, S.R. Park, H.K. Yang, et al., Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomized phase 3 trial, Lancet Oncol. 15 (2014) 1389–1396.

[7] K. Shin, S.J. Park, J. Lee, et al., Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage, BMC Cancer 19 (2019) 1252.

[8] J.H. Kim, S.S. Park, C.M. Lee, et al., Efficacy of adjuvant S-1 versus XELOX chemotherapy for patients with gastric cancer after D2 lymph node dissection: a retrospective, multi-center observational study, Ann. Surg. Oncol. 25 (2018) 1176–1183.

[9] H. Zhang, H. Liu, Z. Shen, et al., Tumor-infiltrating neutrophils is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer, Ann Surg 267 (2018) 311–318.

[10] Y. Jiang, J. Xie, Z. Han, et al., Immunomarker support vector machine classifier for prediction of gastric cancer survival and adjuvant chemotherapeutic benefit, Clin. Cancer Res. 24 (2018) 5574–5584.

[11] J.H. Cheong, H.K. Yang, H. Kim, et al., Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis, Lancet Oncol. 19 (2018) 629–638.

[12] S. Ge, X. Xia, C. Ding, et al., A proteomic landscape of diffuse-type gastric cancer, Nat Commun. 9 (2018) 1012.

[13] B.H. Sohn, J.E. Hwang, H.J. Jang, et al., Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project, Clin. Cancer Res. 23 (2017) 4441–4449.

[14] Y. Jiang, T. Li, X. Liang, et al., Association of adjuvant chemotherapy with survival in patients with stage II or III gastric cancer, JAMA Surg. 152 (2017), e171087.

[15] F. Jorio, T.A. Knijnenburg, D.J. Vist, et al., A landscape of pharmacogenomic interactions in cancer, Cell 166 (2016) 740–754.

[16] I. Diboun, L. Wernisch, C.A. Orengo, M. Kolzenburg, Microarray analysis after RNA amplification can detect pronounced differences in gene expression using limma, BMC Genom. 7 (2006) 252.

[17] Cancer genome atlas research N. Comprehensive molecular characterization of gastric adenocarcinoma, Nature 513 (2014) 202–209.

[18] R. Gristescu, J. Lee, M. Neboutyn, et al., Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes, Nat. Med. 21 (2015) 449–456.

[19] K. Washington, 7th edition of the AJCC cancer staging manual: stomach, Ann. Surg. Oncol. 17 (2010) 3077–3079.

[20] Y. Wang, J. Li, Y. Xia, et al., Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy, J. Clin. Oncol. 31 (2013) 1188–1195.

[21] Y.Q. Huang, G.H. Liang, L. He, et al., Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer, J. Clin. Oncol. 34 (2016) 2157–2164.

[22] W.J. Chae, A.L. Bothwell, Dickkopf1: an immunomodulatory ligand and WNT antagonist in pathological inflammation, Differentiation 108 (2019) 33–39.

[23] M.E. Meneezes, D.J. Devine, L.A. Shevde, R.S. Samant, Dickkopf1: a tumor suppressor or metastasis promoter? Int. J. Cancer 130 (2012) 1477–1483.

[24] N. Shino, H. Kimura, R. Sada, et al., Activation of the Dickkopf1-CKAP4 pathway is associated with poor prognosis of esophageal cancer and anti-CKAP4 antibody may be a new therapeutic drug, Oncogene 37 (2018) 3471–3484.

[25] X. Zhaung, H. Zhang, X. Li, et al., Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1, Nat Cell Biol. 19 (2017) 1274–1285.

[26] H. Hirata, Y. Hinoda, K. Nakajima, et al., Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma, Int J Cancer 128 (2011) 1793–1803.

[27] S. Ma, S. Liang, H. Jiao, et al., Human umbilical cord mesenchymal stem cells inhibit C6 glioma growth via secretion of dickkopf-1 (Dkk1), Mol. Cell Biochem. 385 (2014) 277–286.

[28] H.Y. Chu, Z. Chen, L. Wang, et al., Dickkopf1–: a promising target for cancer immunotherapy, Front Immunol. 12 (2021), 658097.

[29] X. Jia, N. Li, C. Peng, et al., miR-493 mediated DKK1 down-regulation confers proliferation, invasion and chemo-resistance in gastric cancer cells, Oncotarget 7 (2016) 7044–7054.

[30] N. Shinno, H. Kimura, R. Sada, et al., Activation of the Dickkopf1-CKAP4 pathway is associated with poor prognosis of esophageal cancer and anti-CKAP4 antibody may be a new therapeutic drug, Oncogene 37 (2018) 3471–3484.

[31] S. Ma, S. Liang, H. Jiao, et al., Human umbilical cord mesenchymal stem cells inhibit C6 glioma growth via secretion of dickkopf-1 (Dkk1), Mol. Cell Biochem. 385 (2014) 277–286.

[32] B. Wang, J. Liu, L.N. Ma, et al., Chimeric 5/35 adenovirus-mediated Dickkopf-1 overexpression suppressed tumorigenicity of CD44(+) gastric cancer cells via attenuating WNT signaling, J. Gastroenterol. 48 (2013) 798–808.

[33] S.A. Hong, S.H. Yoo, H.H. Lee, et al., Prognostic value of Dickkopf1 and ss-catenin expression in advanced gastric cancer, BMC Cancer 18 (2018) 506.

[34] X. Jia, F. Hui, X. Qin, et al., Diagnosis accuracy and prognostic significance of the Dickkopf-1 protein in gastrointestinal carcinomas: systematic review and network meta-analysis, J. Cancer 11 (2020) 7091–7100.

[35] Q.R. Liu, Y.F. Li, Z.Q. Deng, J.Q. Cao, Prognostic significance of Dickkopf-1 in gastric cancer survival: a meta-analysis, Genet Test Mol. Biomarkers 20 (2016) 170–175.

[36] C. Cai, X. Zhi, The Wnt/beta-catenin pathway regulates self-renewal of cancer stem-like cells in human gastric cancer, Mol. Med. Rep. 5 (2012) 2164–2169.